Australia, Oct. 29 -- Skyhawk Therapeutics Inc., owns the trademark (2644072) for 'DUHUNTX' till April 13, 2036.
Status: registered:
Registered/protected
Class: 5 [Pharmaceuticals, namely, small molecule therapeutic preparations for the correction of RNA expression and alteration of RNA translation, used in the treatment of Huntington's Disease]
Type of Mark: Word
Date of Acceptance: April 14
Registration Advertised: Oct. 28
For further details contact Clayton Utz.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2644072.
Disclaimer: Curated by HT Syndication.
